Children with solid tumors, most of which are malignant, have an
excellent prognosis when treated on contemporary regimens. These regimens, which
incorporate chemotherapeutic agents and treatment modalities used for many
decades, have evolved to improve relapse-free survival and reduce long-term
toxicity. This review discusses the evolution of the treatment regimens employed
for management of the most common solid tumors, emphasizing the similarities
between contemporary and historical regimens. These similarities allow the use
of historical patient cohorts to identify the late effects of successful therapy
and to evaluate remedial interventions for these adverse effects.